FDA head calls for investigation into approval of controversial Alzheimer’s drug

In a letter, FDA Commissioner Janet Woodcock wrote that she’s concerned about “contacts between representatives from Biogen and FDA during the review process, including some that may have occurred outside of the formal correspondence process.”

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting